PDCD1 and non-small cell lung carcinoma: Multiple clinical trials have established the overall survival benefit of monoclonal antibodies targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) and the cytotoxic T-Lymphocyte associated protein 4 (CTLA4) in advanced NSCLC (18).